{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:57:11Z","timestamp":1761292631584},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"17","license":[{"start":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000},"content-version":"vor","delay-in-days":2658,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0\/uk\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This work provides an analysis of across-target bioactivity results in the screening data deposited in PubChem. Two alternative approaches for grouping-related targets are used to examine a compound's across-target bioactivity. This analysis identifies compounds that are selectively active against groups of protein targets that are identical or similar in sequence. This analysis also identifies compounds that are bioactive across unrelated targets. Statistical distributions of compound' across-target selectivity provide a survey to evaluate target specificity of compounds by deriving and analyzing bioactivity profile across a wide range of biological targets for tested small molecules in PubChem. This work enables one to select target specific inhibitors, identify promiscuous compounds and better understand the biological mechanisms of target-small molecule interactions.<\/jats:p>\n               <jats:p>Contact: \u00a0ywang@ncbi.nlm.nih.gov; bryant@ncbi.nlm.nih.gov<\/jats:p>","DOI":"10.1093\/bioinformatics\/btp380","type":"journal-article","created":{"date-parts":[[2009,6,24]],"date-time":"2009-06-24T01:31:43Z","timestamp":1245807103000},"page":"2251-2255","source":"Crossref","is-referenced-by-count":27,"title":["A survey of across-target bioactivity results of small molecules in PubChem"],"prefix":"10.1093","volume":"25","author":[{"given":"Lianyi","family":"Han","sequence":"first","affiliation":[{"name":"National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD 20894, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD 20894, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Bryant","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD 20894, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,6,23]]},"reference":[{"key":"2023013112103645900_B1","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: a new generation of protein database search programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"2023013112103645900_B2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1126\/science.1105511","article-title":"NIH Molecular Libraries Initiative","volume":"306","author":"Austin","year":"2004","journal-title":"Science"},{"key":"2023013112103645900_B3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/cmdc.200700036","article-title":"Modeling promiscuity based on in vitro safety pharmacology profiling data","volume":"2","author":"Azzaoui","year":"2007","journal-title":"Chem. Med. Chem."},{"key":"2023013112103645900_B4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1367-5931(97)80111-1","article-title":"New technologies for high-throughput screening","volume":"1","author":"Burbaum","year":"1997","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2023013112103645900_B5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.65","article-title":"Small-molecule aggregates inhibit amyloid polymerization","volume":"4","author":"Feng","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"2023013112103645900_B6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1359-6446(04)03275-1","article-title":"High-throughput drug discovery: what can we expect from HTS?","volume":"10","author":"Gribbon","year":"2005","journal-title":"Drug Discov. Today"},{"key":"2023013112103645900_B7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cbpa.2004.04.003","article-title":"Pursuing the leadlikeness concept in pharmaceutical research","volume":"8","author":"Hann","year":"2004","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2023013112103645900_B8","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/carcin\/bgm110","article-title":"Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1","volume":"28","author":"Lee","year":"2007","journal-title":"Carcinogenesis"},{"key":"2023013112103645900_B9","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1158\/0008-5472.CAN-05-3310","article-title":"Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity","volume":"66","author":"Lu","year":"2006","journal-title":"Cancer Res."},{"key":"2023013112103645900_B10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.drudis.2006.02.001","article-title":"Critical review of the role of HTS in drug discovery","volume":"11","author":"Macarron","year":"2006","journal-title":"Drug Discov. Today"},{"key":"2023013112103645900_B11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.pa.27.040187.001205","article-title":"Computer-aided drug design","volume":"27","author":"Marshall","year":"1987","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2023013112103645900_B12","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1021\/jm010533y","article-title":"A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening","volume":"45","author":"McGovern","year":"2002","journal-title":"J. Med. Chem."},{"key":"2023013112103645900_B13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nbt0908-983","article-title":"Data completeness\u2013the Achilles heel of drug-target networks","volume":"26","author":"Mestres","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"2023013112103645900_B14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0140-6736(03)15370-6","article-title":"Research and development costs for drugs","volume":"363","author":"Riggs","year":"2004","journal-title":"Lancet"},{"key":"2023013112103645900_B15","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1021\/jm0340896","article-title":"Effect of detergent on \u2018promiscuous\u2019 inhibitors","volume":"46","author":"Ryan","year":"2003","journal-title":"J. Med. Chem."},{"key":"2023013112103645900_B16","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1021\/jm030191r","article-title":"Identification and prediction of promiscuous aggregating inhibitors among known drugs","volume":"46","author":"Seidler","year":"2003","journal-title":"J. Med. Chem."},{"key":"2023013112103645900_B17","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1211\/0022357044021","article-title":"Inhibition of human cytochromes P450 by components of Ginkgo biloba","volume":"56","author":"von Moltke","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"2023013112103645900_B18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S1359-6446(05)03632-9","article-title":"Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development","volume":"10","author":"Whitebread","year":"2005","journal-title":"Drug Discov. Today"},{"key":"2023013112103645900_B19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijantimicag.2008.06.010","article-title":"D-Alanine:D-alanine ligase as a new target for the flavonoids quercetin and apigenin","volume":"32","author":"Wu","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2023013112103645900_B20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1091867","article-title":"Medicine. The NIH Roadmap","volume":"302","author":"Zerhouni","year":"2003","journal-title":"Science"}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/25\/17\/2251\/48993451\/bioinformatics_25_17_2251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/25\/17\/2251\/48993451\/bioinformatics_25_17_2251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T21:32:18Z","timestamp":1675200738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/25\/17\/2251\/210726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,23]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/btp380","relation":{},"ISSN":["1367-4811","1367-4803"],"issn-type":[{"value":"1367-4811","type":"electronic"},{"value":"1367-4803","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,9,1]]},"published":{"date-parts":[[2009,6,23]]}}}